Sign in Subscribe
Securities law

Amedisys Inc. Files Form 8-K Regarding Proposed Final Judgment with the U.S. District Court for the District of Maryland

Strategic Insights

— 2 min read

Amedisys Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on August 7, 2025, regarding a proposed final judgment with the U.S. District Court for the District of Maryland. The proposed final judgment, agreed to by Amedisys and UnitedHealth Group, aims to resolve opposition to the previously announced merger transaction. The transaction requires divestitures within 75 days of the court's entry of an asset preservation/hold separate stipulation and order or within 60 days of receipt of all necessary merger clearances under Indiana and West Virginia law, whichever is later.

Key Takeaways:

  • Amedisys Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission on August 7, 2025, regarding a proposed final judgment with the U.S. District Court for the District of Maryland.
  • The proposed final judgment, agreed to by Amedisys and UnitedHealth Group, aims to resolve opposition to the previously announced merger transaction.
  • The proposed final judgment would require divestitures within 75 days of the court's entry of an asset preservation/hold separate stipulation and order or within 60 days of receipt of all necessary merger clearances under Indiana and West Virginia law, whichever is later.
  • The Proposed Final Judgment would require Amedisys and UnitedHealth Group to carry out certain divestitures as part of the Merger Agreement.
  • The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act, 15 U.S.C. § 16, for the limited purpose of determining whether the Proposed Final Judgment is in the public interest.
  • The Merger remains subject to certain conditions to the closing of the transactions contemplated by the merger agreement.
  • Amedisys has cautioned against relying on forward-looking statements, which may differ materially from actual results due to various factors, including the termination of the Merger Agreement or the inability to complete the Merger on the anticipated terms.
  • Richard Ashworth, President and Chief Executive Officer of Amedisys, signed the report on August 7, 2025.

Statistics:

  • The proposed final judgment would require divestitures within 75 days of the court's entry of an asset preservation/hold separate stipulation and order, or within 60 days of receipt of all necessary merger clearances under Indiana and West Virginia law, whichever is later.
  • Amedisys Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on August 7, 2025.
  • The Merger Agreement was dated June 26, 2023, and was modified by a waiver dated December 26, 2024.
  • The Proposed Final Judgment is subject to judicial approval under the Antitrust Procedures and Penalties Act, 15 U.S.C. § 16, for the limited purpose of determining whether the Proposed Final Judgment is in the public interest.

Sources:

  • UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
  • U.S. Private Securities Litigation Reform Act of 1995
  • Securities Exchange Act of 1934
  • Antitrust Procedures and Penalties Act, 15 U.S.C. § 16

Read more